Benzinga | Jun 11, 2021 09:05AM EDT

Constellation Pharmaceuticals Highlights Presentation Of Three Posters Relating To MANIFEST Trial Of Pelabresib At European Hematology Association Annual Meeting

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting. The data in these posters are based on a data cutoff of September 29, 2020 from the MANIFEST Phase 2 clinical trial and reflect an analysis of pelabresib clinical and translational activity.